REFERENCES SCIT APPENDIX

1.

Creticos PS, Reed CE, Norman PS, et al. Ragweed immunotherapy in adult asthma. N Engl J Med. 1996;334(8):501–6. [PubMed: 8559203]

2.

Hill DJ, Hosking CS, Shelton MJ, Turner MW. Failure of hyposensitisation in treatment of children with grass-pollen asthma. Br Med J (Clin Res Ed). 1982;284(6312):306–9. [PMC free article: PMC1495893] [PubMed: 6800440]

3.

Altintas D, Akmanlar N, Guneser S, et al. Comparison between the use of adsorbed and aqueous immunotherapy material in Dermatophagoides pteronyssinus sensitive asthmatic children. Allergol Immunopathol (Madr). 1999;27(6):309–17. [PubMed: 10611556]

4.

Bousquet J, Calvayrac P, Guerin B, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. I. In vivo and in vitro parameters after a short course of treatment. J Allergy Clin Immunol. 1985;76(5):734–44. [PubMed: 4056259]

5.

Bousquet J, Hejjaoui A, Clauzel AM, et al. Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. II. Prediction of efficacy of immunotherapy. J Allergy Clin Immunol. 1988;82(6):971–7. [PubMed: 3204255]

6.

Garcia-Ortega P, Merelo A, Marrugat J, Richart C. Decrease of skin and bronchial sensitization following short-intensive scheduled immunotherapy in mite-allergic asthma. Chest. 1993;103(1):183–7. [PubMed: 8417875]

7.

Pifferi M, Baldini G, Marrazzini G, et al. Benefits of immunotherapy with a standardized Dermatophagoides pteronyssinus extract in asthmatic children: a three-year prospective study. Allergy. 2002;57(9):785–90. [PubMed: 12169173]

8.

Van Bever HP, Stevens WJ. Effect of hyposensitization upon the immediate and late asthmatic reaction and upon histamine reactivity in patients allergic to house dust mite (Dermatophagoides pteronyssinus). Eur Respir J. 1992;5(3):318–22. [PubMed: 1572445]

9.

Van Bever HP, Stevens WJ. Evolution of the late asthmatic reaction during immunotherapy and after stopping immunotherapy. J Allergy Clin Immunol. 1990;86(2):141–6. [PubMed: 2384645]

10.

Wang H, Lin X, Hao C, et al. A double-blind, placebo-controlled study of house dust mite immunotherapy in Chinese asthmatic patients. Allergy. 2006;61(2):191–7. [PubMed: 16409195]

11.

Schubert R, Eickmeier O, Garn H, et al. Safety and immunogenicity of a cluster specific immunotherapy in children with bronchial asthma and mite allergy. Int Arch Allergy Immunol. 2009;148(3):251–60. [PubMed: 18849616]

12.

Kohno Y, Minoguchi K, Oda N, et al. Effect of rush immunotherapy on airway inflammation and airway hyperresponsiveness after bronchoprovocation with allergen in asthma. J Allergy Clin Immunol. 1998;102(6 Pt 1):927–34. [PubMed: 9847433]

13.

Maestrelli P, Zanolla L, Pozzan M, Fabbri LM. Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mite. J Allergy Clin Immunol. 2004;113(4):643–9. [PubMed: 15100667]

14.

Olsen OT, Larsen KR, Jacobsan L, Svendsen UG. A 1-year, placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults. Allergy. 1997;52(8):853–9. [PubMed: 9284985]

15.

Ohman JL Jr, Findlay SR, Leitermann KM. Immunotherapy in cat-induced asthma. Double-blind trial with evaluation of in vivo and in vitro responses. J Allergy Clin Immunol. 1984;74(3 Pt 1):230–9. [PubMed: 6206105]

16.

Van Metre TE Jr, Marsh DG, Adkinson NF Jr, et al. Immunotherapy for cat asthma. J Allergy Clin Immunol. 1988;82(6):1055–68. [PubMed: 2462581]

17.

Valovirta E, Viander M, Koivikko A, Vanto T, Ingeman L. Immunotherapy in allergy to dog. Immunologic and clinical findings of a double-blind study. Ann Allergy. 1986;57(3):173–9. [PubMed: 3752618]

18.

Valovirta E, Koivikko A, Vanto T, Viander M, Ingeman L. Immunotherapy in allergy to dog: a double-blind clinical study. Ann Allergy. 1984;53(1):85–8. [PubMed: 6742528]

19.

Malling HJ, Dreborg S, Weeke B. Diagnosis and immunotherapy of mould allergy. V. Clinical efficacy and side effects of immunotherapy with Cladosporium herbarum. Allergy. 1986;41(7):507–19. [PubMed: 3789332]

20.

Adkinson NF Jr, Eggleston PA, Eney D, et al. A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med. 1997;336(5):324–31. [PubMed: 9011784]

21.

Limb SL, Brown KC, Wood RA, Eggleston PA, Hamilton RG, Adkinson NF Jr. Long-term immunologic effects of broad-spectrum aeroallergen immunotherapy. Int Arch Allergy Immunol. 2006;140(3):245–51. [PubMed: 16691031]

22.

Polosa R, Li Gotti F, Mangano G, et al. Effect of immunotherapy on asthma progression, BHR and sputum eosinophils in allergic rhinitis. Allergy. 2004;59(11):1224–8. [PubMed: 15461606]

23.

Polosa R, Ligotti F, Mangano G, et al. Seasonal variability in BHR and sputum cells count in subjects with rhinitis and effect of 3 yrs specific immunotherapy; American Thoracic Society 99th International Conference; 2003.

24.

Van Metre TE, Adkinson NF Jr, Amodio FJ, et al. A comparative study of the effectiveness of the Rinkel method and the current standard method of immunotherapy for ragweed pollen hay fever. J Allergy Clin Immunol. 1980;66(6):500–13. [PubMed: 6159384]

25.

Van Metre TE Jr, Adkinson NF Jr, Amodio FJ, et al. A comparison of immunotherapy schedules for injection treatment of ragweed pollen hay fever. J Allergy Clin Immunol. 1982;69(2):181–93. [PubMed: 7056949]

26.

Craps LP. [The prevention of asthma: goals, methods, results]. Rev Med Brux. 1987;8(2):59–62. [PubMed: 3105020]

27.

Ariano R, Panzani RC, Augeri G. Double-blind placebo controlled specific immunotherapy with mixed Cupressaceae taxodiaceae pollens in respiratory allergy to Cupressus sempervirens. Allergol Immunopathol (Madr). 1997;25(1):23–9. [PubMed: 9111873]

28.

Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 1999;341(7):468–75. [PubMed: 10441602]

29.

Reid MJ, Moss RB, Hsu YP, Kwasnicki JM, Commerford TM, Nelson BL. Seasonal asthma in northern California: allergic causes and efficacy of immunotherapy. J Allergy Clin Immunol. 1986;78(4 Pt 1):590–600. [PubMed: 3771951]

30.

Guimaraes Junqueir de Queiros M, Oliveira Silva DA, Alves R, et al. Mite-specific immunotherapy using allergen and/or bacterial extracts in atopic patients in Brazil. J Investig Allergol Clin Immunol. 2008;18(2):84–92. [PubMed: 18447136]

31.

McHugh SM, Lavelle B, Kemeny DM, Patel S, Ewan PW. A placebo-controlled trial of immunotherapy with two extracts of Dermatophagoides pteronyssinus in allergic rhinitis, comparing clinical outcome with changes in antigen-specific IgE, IgG, and IgG subclasses. J Allergy Clin Immunol. 1990;86(4 Pt 1):521–31. [PubMed: 1699985]

32.

Ewan PW, Alexander MM, Snape C, Ind PW, Agrell B, Dreborg S. Effective hyposensitization in allergic rhinitis using a potent partially purified extract of house dust mite. Clin Allergy. 1988;18(5):501–8. [PubMed: 3069238]

33.

Nanda A, O’Connor M, Anand M, et al. Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract. J Allergy Clin Immunol. 2004;114(6):1339–44. [PubMed: 15577832]

34.

Crimi N, Li Gotti F, Mangano G, et al. A randomized, controlled study of specific immunotherapy in monosensitized subjects with seasonal rhinitis: effect on bronchial hyperresponsiveness, sputum inflammatory markers and development of asthma symptoms. Ann Ital Med Int. 2004;19(2):98–108. [PubMed: 15317270]

35.

Bernstein IL, Tennenbaum J, Georgakis N, Kessler F, Krumholz R. Fraction A: a new immunotherapeutic approach for ragweed pollinosis. Int Arch Allergy Appl Immunol. 1976;50(2):181–91. [PubMed: 1107233]

36.

Frew AJ, Powell RJ, Corrigan CJ, Durham SR. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006;117(2):319–25. [PubMed: 16461133]

37.

Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ. 1991;302(6771):265–9. [PMC free article: PMC1668945] [PubMed: 1998791]

38.

Durham SR, Birk AO, Andersen JS. Days with severe symptoms: an additional efficacy endpoint in immunotherapy trials. Allergy. 2010 [PubMed: 20608918]

39.

Durham SR, Ying S, Varney VA, et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol. 1996;97(6):1356–65. [PubMed: 8648033]

40.

Shamji MH, Ljorring C, Francis JN, et al. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy. Allergy: European Journal of Allergy and Clinical Immunology. 2012;67(2):217–226. [PubMed: 22077562]

41.

James LK, Shamji MH, Walker SM, et al. Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. The Journal of allergy and clinical immunology. 2011:509–516. e1–5. [PubMed: 21281875]

42.

Walker SM, Pajno GB, Lima MT, Wilson DR, Durham SR. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. J Allergy Clin Immunol. 2001;107(1):87–93. [PubMed: 11149996]

43.

Frostad AB, Grimmer O, Sandvik L, Moxnes A, Aas K. Clinical effects of hyposensitization using a purified allergen preparation from Timothy pollen as compared to crude aqueous extracts from Timothy pollen and a four-grass pollen mixture respectively. Clin Allergy. 1983;13(4):337–57. [PubMed: 6136346]

44.

Klimek L, Wolf H, Mewes T, et al. The effect of short-term immunotherapy with molecular standardized grass and rye allergens on eosinophil cationic protein and tryptase in nasal secretions. J Allergy Clin Immunol. 1999;103(1 Pt 1):47–53. [PubMed: 9893184]

45.

Leynadier F, Banoun L, Dollois B, et al. Immunotherapy with a calcium phosphate-adsorbed five-grass-pollen extract in seasonal rhinoconjunctivitis: a double-blind, placebo-controlled study. Clin Exp Allergy. 2001;31(7):988–96. [PubMed: 11467988]

46.

Moller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol. 2002;109(2):251–6. [PubMed: 11842293]

47.

Niggemann B, Jacobsen L, Dreborg S, et al. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy. 2006;61(7):855–9. [PubMed: 16792584]

48.

Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;62(8):943–8. [PubMed: 17620073]

49.

Olsen OT, Frolund L, Heinig J, Jacobsen L, Svendsen UG. A double-blind, randomized study investigating the efficacy and specificity of immunotherapy with Artemisia vulgaris or Phleum pratense/betula verrucosa. Allergol Immunopathol (Madr). 1995;23(2):73–8. [PubMed: 8526170]

50.

Zenner HP, Baumgarten C, Rasp G, et al. Short-term immunotherapy: a prospective, randomized, double-blind, placebo-controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis. J Allergy Clin Immunol. 1997;100(1):23–9. [PubMed: 9257783]

51.

Dreborg S, Lee TH, Kay AB, Durham SR. Immunotherapy Is Allergen-Specific: A Double-Blind Trial of Mite or Timothy Extract in Mite and Grass Dual-Allergic Patients. International Archives of Allergy and Immunology. 2011;158(1):63–70. [PubMed: 22212720]

52.

Ariano R, Berto P, Tracci D, Incorvaia C, Frati F. Pharmacoeconomics of allergen immunotherapy compared with symptomatic drug treatment in patients with allergic rhinitis and asthma. Allergy Asthma Proc. 2006;27(2):159–63. [PubMed: 16724637]

53.

Ferrer M, Burches E, Pelaez A, et al. Double-blind, placebo-controlled study of immunotherapy with Parietaria judaica: clinical efficacy and tolerance. J Investig Allergol Clin Immunol. 2005;15(4):283–92. [PubMed: 16433210]

54.

Naclerio RM, Proud D, Moylan B, et al. A double-blind study of the discontinuation of ragweed immunotherapy. J Allergy Clin Immunol. 1997;100(3):293–300. [PubMed: 9314339]

55.

Iliopoulos O, Proud D, Adkinson NF Jr, et al. Effects of immunotherapy on the early, late, and rechallenge nasal reaction to provocation with allergen: changes in inflammatory mediators and cells. J Allergy Clin Immunol. 1991;87(4):855–66. [PubMed: 2013680]

56.

Arvidsson MB, Lowhagen O, Rak S. Allergen specific immunotherapy attenuates early and late phase reactions in lower airways of birch pollen asthmatic patients: a double blind placebo-controlled study. Allergy. 2004;59(1):74–80. [PubMed: 14674937]

57.

Arvidsson MB, Lowhagen O, Rak S. Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy. J Allergy Clin Immunol. 2002;109(5):777–83. [PubMed: 11994699]

58.

Munoz Lejarazu D, Bernaola G, Fernandez E, et al. Seasonal versus perennial immunotherapy: evaluation after three years of treatment. J Investig Allergol Clin Immunol. 1993;3(4):210–6. [PubMed: 8281355]

59.

Nouri-Aria KT, Wachholz PA, Francis JN, et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol. 2004;172(5):3252–9. [PubMed: 14978133]

60.

Muro MD, Tabar AI, Lizaso MT, Quirce S, Polo F, Garcia BE. Cluster versus conventional immunotherapy in patients allergic to Dermatophagoides pteronyssinus: a controlled study of in vivo and in vitro parameters. J Investig Allergol Clin Immunol. 1999;9(3):146–54. [PubMed: 10412676]

61.

Tabar AI, Echechipia S, Garcia BE, et al. Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus. J Allergy Clin Immunol. 2005;116(1):109–18. [PubMed: 15990782]

62.

Newton DA, Maberley DJ, Wilson R. House dust mite hyposensitization. Br J Dis Chest. 1978;72(1):21–8. [PubMed: 341952]

63.

Prieto L, Palacios R, Aldana D, et al. Effect of allergen-specific immunotherapy with purified Alt a1 on AMP responsiveness, exhaled nitric oxide and exhaled breath condensate pH: a randomized double blind study. Allergy Asthma Clin Immunol. 2010;6(1):27. [PMC free article: PMC2949816] [PubMed: 20846390]

64.

Horst M, Hejjaoui A, Horst V, Michel FB, Bousquet J. Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract. J Allergy Clin Immunol. 1990;85(2):460–72. [PubMed: 2406323]

65.

Tabar AI, Lizaso MT, Garcia BE, et al. Double-blind, placebo-controlled study of Alternaria alternata immunotherapy: clinical efficacy and safety. Pediatr Allergy Immunol. 2008;19(1):67–75. [PubMed: 17651380]

66.

Akmanlar N, Altintas DU, Guneser KS, Yilmaz M, Bingol G. Comparison of conventional and rush immunotherapy with der PI in childhood respiratory allergy. Allergol Immunopathol (Madr). 2000;28(4):213–8. [PubMed: 11022267]

67.

Pichler CE, Marquardsen A, Sparholt S, et al. Specific immunotherapy with Dermatophagoides pteronyssinus and D. farinae results in decreased bronchial hyperreactivity. Allergy. 1997;52(3):274–83. [PubMed: 9140517]

68.

Varney VA, Tabbah K, Mavroleon G, Frew AJ. Usefulness of specific immunotherapy in patients with severe perennial allergic rhinitis induced by house dust mite: a double-blind, randomized, placebo-controlled trial. Clin Exp Allergy. 2003;33(8):1076–82. [PubMed: 12911781]

69.

Petersen BN, Janniche H, Munch EP, et al. Immunotherapy with partially purified and standardized tree pollen extracts. I. Clinical results from a three-year double-blind study of patients treated with pollen extracts either of birch or combinations of alder, birch and hazel. Allergy. 1988;43(5):353–62. [PubMed: 3046405]

70.

Hedlin G, Wille S, Browaldh L, et al. Immunotherapy in children with allergic asthma: effect on bronchial hyperreactivity and pharmacotherapy. J Allergy Clin Immunol. 1999;103(4):609–14. [PubMed: 10200009]

71.

Cantani A, Arcese G, Lucenti P, Gagliesi D, Bartolucci M. A three-year prospective study of specific immunotherapy to inhalant allergens: evidence of safety and efficacy in 300 children with allergic asthma. J Investig Allergol Clin Immunol. 1997;7(2):90–7. [PubMed: 9161933]

72.

Mirone C, Albert F, Tosi A, et al. Efficacy and safety of subcutaneous immunotherapy with a biologically standardized extract of Ambrosia artemisiifolia pollen: a double-blind, placebo-controlled study. Clin Exp Allergy. 2004;34(9):1408–14. [PubMed: 15347374]

73.

Osterballe O. Immunotherapy with grass pollen major allergens. Allergy. 1982;37(6):379–88. [PubMed: 7137533]

74.

Osterballe O, Lowenstein H, Prahl P, Skov P, Weeke B. Immunotherapy in hay fever with two major allergens 19, 25 and partially purified extract of timothy grass pollen. A controlled double blind study. In vitro variables, season i. Allergy. 1981;36(3):183–99. [PubMed: 7015911]

75.

Osterballe O. Immunotherapy in hay fever with two major allergens 19, 25 and partially purified extract of timothy grass pollen. A controlled double blind study. In vivo variables, season I. Allergy. 1980;35(6):473–89. [PubMed: 7008640]

76.

Osterballe O. Side effects during immunotherapy with purified grass pollen extracts. Allergy. 1982;37(8):553–62. [PubMed: 7181051]

77.

Pence HL, Mitchell DQ, Greely RL, Updegraff BR, Selfridge HA. Immunotherapy for mountain cedar pollinosis. A double-blind controlled study. J Allergy Clin Immunol. 1976;58(1 PT 1):39–50. [PubMed: 780406]

78.

Rak S, Heinrich C, Jacobsen L, Scheynius A, Venge P. A double-blinded, comparative study of the effects of short preseason specific immunotherapy and topical steroids in patients with allergic rhinoconjunctivitis and asthma. J Allergy Clin Immunol. 2001;108(6):921–8. [PubMed: 11742269]

79.

Rak S, Heinrich C, Scheynius A. Comparison of nasal immunohistology in patients with seasonal rhinoconjunctivitis treated with topical steroids or specific allergen immunotherapy. Allergy. 2005;60(5):643–9. [PubMed: 15813810]

80.

Dreborg S, Agrell B, Foucard T, Kjellman NI, Koivikko A, Nilsson S. A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. I. Clinical results. Allergy. 1986;41(2):131–40. [PubMed: 3518526]

81.

Kuna P, Kaczmarek J, Kupczyk M. Efficacy and safety of immunotherapy for allergies to Alternaria alternata in children. The Journal of allergy and clinical immunology. 2011:502–508. e1–6. [PubMed: 21281874]

82.

Weyer A, Donat N, L’Heritier C, et al. Grass pollen hyposensitization versus placebo therapy. I. Clinical effectiveness and methodological aspects of a pre-seasonal course of desensitization with a four-grass pollen extract. Allergy. 1981;36(5):309–17. [PubMed: 7032341]

83.

Bousquet J, Becker WM, Hejjaoui A, et al. Differences in clinical and immunologic reactivity of patients allergic to grass pollens and to multiple-pollen species. II. Efficacy of a double-blind, placebo-controlled, specific immunotherapy with standardized extracts. J Allergy Clin Immunol. 1991;88(1):43–53. [PubMed: 2071784]

84.

Bousquet J, Hejjaoui A, Becker WM, et al. Clinical and immunologic reactivity of patients allergic to grass pollens and to multiple pollen species. I. Clinical and immunologic characteristics. J Allergy Clin Immunol. 1991;87(3):737–46. [PubMed: 2005328]

85.

Chakraborty P, Roy I, Chatterjee S, Chanda S, Gupta-Bharracharya S. Phoenix sylvestris Roxb pollen allergy: a 2-year randomized controlled trial and follow-up study of immunotherapy in patients with seasonal allergy in an agricultural area of West Bengal, India. J Investig Allergol Clin Immunol. 2006;16(6):377–84. [PubMed: 17153886]

86.

Dolz I, Martinez-Cocera C, Bartolome JM, Cimarra M. A double-blind, placebo-controlled study of immunotherapy with grass-pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy. Allergy. 1996;51(7):489–500. [PubMed: 8863926]

87.

Alvarez-Cuesta E, Cuesta-Herranz J, Puyana-Ruiz J, Cuesta-Herranz C, Blanco-Quiros A. Monoclonal antibody-standardized cat extract immunotherapy: risk-benefit effects from a double-blind placebo study. J Allergy Clin Immunol. 1994;93(3):556–66. [PubMed: 8151058]

88.

Varney VA, Edwards J, Tabbah K, Brewster H, Mavroleon G, Frew AJ. Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial. Clin Exp Allergy. 1997;27(8):860–7. [PubMed: 9291281]

89.

Tabar AI, Arroabarren E, Echechipia S, Garcia BE, Martin S, Alvarez-Puebla MJ. Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergy. Journal of Allergy and Clinical Immunology. 2011;127(1):57–63. e3. [PubMed: 21211641]

90.

Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. Allergol Immunopathol (Madr). 1990;18(5):277–84. [PubMed: 2097894]